Biomarkers in Samples From Young Patients With Neuroblastoma

ROR1 as a Novel Target for Neuroblastoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01358604

Enrollment

Registered

2011-05-23

Start date

2011-05-31

Completion date

2016-04-30

Last updated

2016-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroblastoma

Keywords

localized resectable neuroblastoma, recurrent neuroblastoma, regional neuroblastoma, stage 4S neuroblastoma, localized unresectable neuroblastoma

Brief summary

RATIONALE: Studying samples of tissue and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study studies biomarkers in samples from young patients with neuroblastoma.

Detailed description

OBJECTIVES: Primary * To analyze the expression of ROR1 on the surface of primary neuroblastoma cells. * To investigate the therapeutic potential of anti-ROR1 monoclonal antibodies (mAbs), bispecific antibodies, and immunotoxins in in vitro and in vivo models of neuroblastoma. OUTLINE: Archived bone marrow and tumor tissue samples are analyzed for ROR1 expression by flow cytometry, western blotting, qPCR, and IHC.

Interventions

GENETICpolymerase chain reaction

GENETICprotein expression analysis

GENETICwestern blotting

OTHERflow cytometry

OTHERimmunohistochemistry staining method

OTHERlaboratory biomarker analysis

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 120 Years

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Diagnosed with neuroblastoma * With or without N-myc amplification * Primary tumor samples as frozen tissue in liquid nitrogen or -80 degrees C * Bone marrow samples from high-risk patients as peripheral blood mononuclear cells (PBMC) that have been cryopreserved with DMSO as viable cells to be used for flow cytometry or slides of bone marrow that can be used for immunohistochemistry PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Design outcomes

Primary

Measure	Time frame
ROR1 is expressed on the surface of neuroblastoma cells and constitutes a suitable target for mAb therapy	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026